Cargando…
Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses
“Day-7” myeloid DCs are commonly used in the clinic. However, there is a strong need to develop DCs faster that have the same potent immunostimulatory capacity as “Day-7” myeloid DCs and at the same time minimizing time, labor and cost of DC preparations. Although “2 days” DCs can elicit peptide-spe...
Autores principales: | Chiang, Cheryl Lai-Lai, Hagemann, Andrea R., Leskowitz, Rachel, Mick, Rosemarie, Garrabrant, Thomas, Czerniecki, Brian J., Kandalaft, Lana E., Powell, Daniel J., Coukos, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3237492/ https://www.ncbi.nlm.nih.gov/pubmed/22194898 http://dx.doi.org/10.1371/journal.pone.0028732 |
Ejemplares similares
-
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013) -
Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate
por: Chiang, Cheryl L-L, et al.
Publicado: (2011) -
Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer
por: Kandalaft, Lana E, et al.
Publicado: (2013) -
Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015) -
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
por: Kandalaft, Lana E., et al.
Publicado: (2013)